Faster transmission! Triple mutation” strain discovered in India

India’s second wave of the epidemic is raging, with more than 310,000 new cases of Wuhan pneumonia (novel coronavirus disease, COVID-19) diagnosed in a single day on the 22nd, a global record. The epidemiologists in India warned that a faster spreading “triple mutation” strain of Wuhan pneumonia has been discovered in India!

According to New Delhi Television (NDTV) 21, after the discovery of a double mutant virus in India, there is now a triple mutant virus, which means that three different strains of the virus have combined to form a new variant that has been found in Maharashtra, Delhi for the first time, West Bengal (West Benga) and Chhattisgarh (Chhattisgarh). It is believed to be one of the causes of the recent outbreak in India.

Earlier, Vinod Scaria, a scientist at the Institute of Genetics and Integrative Biology (IGIB) of the Indian Council of Scientific and Industrial Research (CSIR), announced that scientists had discovered a new variant of the virus called B.1.618 in West Bengal, characterized by the E484K and D614G mutations in the stinger protein, which evade and weaken the human immune response to the virus, in addition to six In addition to the E484K and D614G mutations in the spike-in protein, which evade and weaken the human immune response to the virus, there is a chromosomal rearrangement of six nucleotides (H146del and Y145del), making it a triple mutant virus strain.

Madhukar Pai, an Indian epidemiologist who teaches at McGill University in Canada, said, “This mutated virus spreads faster, it makes people sick very quickly, so vaccines have to be constantly adapted and their genomes need to be sequenced out quickly.” But the genome sequencing done in India is less than 1 percent of all cases and there are only 10 laboratories involved in viral genome studies.

Previously E484K has been confirmed to exist in South Africa, Brazil variant of the virus, and Novavax and Jiao Sheng 2 vaccine manufacturers have announced that the phase 3 clinical trial data of its vaccine, South Africa’s effectiveness is significantly lower than other countries, respectively, 60% and 57%, suspected to be due to the E484K mutation in the South African variant of the virus.